TPMT in the treatment of inflammatory bowel disease with azathioprine

We read with interest the recent article by Lennard on the role of thiopurine methyltransferase (TPMT) enzyme in predicting azathioprine related toxicity in patients with inflammatory bowel disease (IBD) (Gut 2002;51:143–6). He concludes that measurement of TPMT activity has no specific role in identifying the risk of significant bone marrow toxicity in long term users of azathioprine. This conclusion is in agreement with other published work and emphasises the importance of ongoing haematological monitoring in IBD patients receiving this drug.

The importance of haematological monitoring in IBD patients receiving this drug. This conclusion is in agreement with other published work and emphasises the importance of ongoing haematological monitoring in IBD patients receiving this drug. The key issue in determining the time of onset of potentially life threatening bone marrow suppression following initiation of azathioprine treatment. These data are not available for patients with IBD.

In a retrospective study, we analysed the time of onset of all drug related toxicity in IBD patients post initiation of azathioprine therapy. A total of 110 consecutive IBD patients with a history of azathioprine use were identified (table 1). Patients were identified from the hospital inpatient enquiry system, IBD clinic, and pharmacy records. Mean azathioprine dose was 2 mg/kg/day (range 1–3). Mean age of the patients on azathioprine was 36.11 years (range 18–78). Seventeen of 110 patients (15%) suffered from azathioprine related early toxicity (table 1). Mean azathioprine dose in those showing drug toxicity was 100 mg/day (50–150). Most (77%) drug related toxic events manifested within the first 12 weeks of therapy (fig 1). However, the mean time of onset of drug related toxicity was not true for bone marrow suppression. The mean duration of treatment in the two patients who experienced this side effect was 11 weeks (range 10–12). Both cases occurred outside the “stringent” eight week monitoring period recommended by the drug’s manufacturer. Hence identification of bone marrow suppression would have been delayed using the current British and manufacturer’s guidelines. Three further episodes of neutropenia were identified during long term (>3 months) treatment in three patients who continued on maintenance azathioprine (mean duration 101 weeks/patient, range 2 weeks to 5 years). In our practice, we feel that significant toxicity during the early (<3 months) period of therapy could have been missed by strictly following existing guidelines.

Early detection of abnormalities in asymptomatic patients helped in dose adjustment with resolution of side effects. In addition, early detection of azathioprine related bone marrow suppression is likely to save lives. We recommend that gastroenterologists employ an extended (three month) period of intensive haematological monitoring after initiation of azathioprine therapy in IBD. Although neutropenia is occasionally observed beyond this point, intensive monitoring for the duration of treatment, which may continue for years, is clearly not practical from a patient or service perspective. However, this serves to emphasise the importance of continuous patient education concerning “alarm symptoms” throughout the duration of azathioprine therapy.

A Qasim, J Seery, M Buckley, C O Morain
Gastroenterology Department, AMNCH, Tallaght, Dublin 24, Ireland
Correspondence to: A Qasim; qasim@cd.ie

**References**


**Author’s reply**

Measurement of thiopurine methyltransferase (TPMT) status, prior to the start of azathioprine therapy, has a role in identifying the TPMT deficient patient at risk of severe myelosuppression and TPMT heterozygous individuals who are prone to early myelosuppression. The risk of azathioprine toxicity is well recognised, but, as the authors state, the matter for debate is the time of onset of potentially life threatening myelosuppression.
Quasim et al state that this information is not available for patients with inflammatory bowel disease (IBD). However, data can be derived from observations in patients or patient groups which may serve as useful guidelines for this time interval.

Reports of azathioprine induced severe myelosuppression in the TPMT deficient patient indicate that bone marrow toxicity is recorded after 3–10 weeks (median 4) of azathioprine therapy. In these reports the drug dosage varied from 1 to 2.9 mg/kg (median 1.7). One patient taking azathioprine at a dosage of 1 mg/kg developed myelosuppression (white blood cell count (WBC) 1.6×10⁹/l, platelets 25×10⁹/l) at 10 weeks while another dosed at 1 mg/kg developed myelosuppression (WBC 3.8×10⁹/l, platelets 9×10⁹/l) within one month of starting azathioprine (2–3 mg/kg) as second line therapy for rheumatic disease.

Weekly full blood counts during the first three months and continuation of, at a minimum, complete blood counts should be monitored within 1.5 months of azathioprine therapy. Similar observations have been made by Schwab and colleagues who reported myelosuppression in a TPMT deficient Crohn’s patient after 1.75 months of azathioprine at 1.5 mg/kg and in two TPMT heterozygous patients after 2.5 and 3 months of therapy at dosages of 1.0 and 1.5 mg/kg, respectively. Additional observation that those individuals with wild-type alleles (“normal” TPMT activity) can experience myelosuppression after weeks or years of azathioprine therapy illustrates the multifactorial nature of myelosuppression in this patient group and supports the need for continued vigilance with respect to blood count monitoring.

Specifically for the patient with Crohn’s disease, Colombel and colleagues have reported that TPMT deficient individuals experience leucopenia or thrombocytopenia within 1.5 months of azathioprine therapy (100–150 mg/day) and that TPMT heterozygotes developed toxicity after 1–18 months (median 4) of therapy. Similar observations have been made by Schwab and colleagues who reported myelosuppression in a TPMT deficient Crohn’s patient after 1.75 months of azathioprine at 1.5 mg/kg and in two TPMT heterozygous patients after 2.5 and 3 months of therapy at dosages of 1.0 and 1.5 mg/kg, respectively. Additional observation that those individuals with wild-type alleles (“normal” TPMT activity) can experience myelosuppression after weeks or years of azathioprine therapy illustrates the multifactorial nature of myelosuppression in this patient group and supports the need for continued vigilance with respect to blood count monitoring.

The drug manufacturer’s guidelines, as stated in the Association of the British Pharmaceutical Industry (ABPI) medicines compendium, advise that at a minimum, complete blood counts should be monitored weekly during the first eight weeks of therapy. The guidelines then continue, “this frequency may be reduced during later therapy to monthly intervals, or at least at intervals no longer than three months”. The data presented in the reports above indicate, particularly for the patient on low dose azathioprine, in whom TPMT status is unknown, close adherence to the ABPI guidelines and continuation of, at a minimum, weekly full blood counts during the first three months of treatment. Because severe bone marrow toxicity can be precipitated by the addition of aminosalicylate derivatives to the azathioprine regimen, the drug manufacturer’s more stringent blood count monitoring scheme should be considered following such adjustments in the combination therapy of refractory IBD.

L Lennard

University of Sheffield, School of Medicine, Academic Unit of Molecular and Clinical Pharmacology, Floor I, Royal Hallamshire Hospital, Glossop Rd, Sheffield S10 2JF, UK; l.lennard@sheffield.ac.uk

www.gutjnl.com

References


Appendectomy and ulcerative colitis

Cosnes et al demonstrated that previous appendectomy is not only associated with a lower incidence of ulcerative colitis, but also with a less severe course of the disease. Although we can fully agree with this result, we disagree with the recommendation that appendectomy in patients genetically at high risk of developing ulcerative colitis may be considered as candidates for appendicectomy for the objectives of preventing the development of ulcerative colitis and also decreasing its severity” (Gut 2002; 51: 803–7).

All previous studies, as well as the present study, have demonstrated an association only between previous appendicitis and ulcerative colitis. It has not been shown that performing appendicectomy in healthy persons at increased risk of developing ulcerative colitis is beneficial. The association may as well have been caused by an unknown confounding factor, both leading to an increased risk of appendectomy and a decreased risk of developing (severe) ulcerative colitis. To illustrate this point is the following theoretical example: an epidemiological study on cardiovascular morbidity finds that the risk of cardiovascular events is inversely related to the risk of developing upper gastrointestinal haemorrhage. This could be due to the factor “treatment with aspirin” that could well explain the increased bleeding risk and the lower incidence of cardiovascular events. The confounding factor is the use of aspirin. It would be wrong to conclude that in patients without a history of bleeding, attempts should be undertaken to induce upper gastrointestinal bleeding in order to prevent cardiovascular morbidity.

Another argument against performing this surgical procedure in healthy persons is the finding that appendicectomy in the absence of an inflamed appendix was not associated with a decreased risk of ulcerative colitis, suggesting that appendicitis rather than appendicectomy protects against ulcerative colitis. Cosnes et al state that these results may not be correct as they included all patients with previous appendicectomy and still found a less severe course. We believe they are incorrectly assuming this, as another possible explanation is that the effect of appendicitis is actually higher than the effect of appendicectomy reported in the present study, which could have been due to the inclusion of patients without appendicitis.

In conclusion, we believe that at present healthy persons at risk of developing ulcerative colitis should not be considered candidates for appendicectomy outside clinical trials as evidence showing that appendicectomy will protect these persons is lacking.

P C J ter Borg, H R van Buuren

Erasmus MC, Rotterdam, the Netherlands

Correspondence to: Dr P C J ter Borg, Dr Molewaterplein 40, Rotterdam, the Netherlands; pterborg@erzonnet.nl

Reference


Authors’ reply

Many French surgeons in 1900 did recommend removing preventively all appendixes of young people (see Marcel Proust, “A l’ombre des jeunes filles en fleur”). That was not our purpose. Indeed, the sentence pointed out by ter Borg and van Buuren in our paper did not give a recommendation but only made a suggestion to consider for appendicectomy patients genetically at high risk of developing ulcerative colitis.

Ter Borg and van Buuren speculate that appendicectomy and a benign course of ulcerative colitis may be linked through a confounding factor but they do not document their hypothesis. In fact, there is a large body of evidence supporting a causal relationship between appendicectomy and no (or benign) ulcerative colitis and the strongest demonstration of this relationship is the protective effect of early appendicectomy in the T cell receptor α (TCR-α) knockout mouse model. Note also that the Swedish study which found that only appendicectomy for inflammatory conditions protects against ulcerative colitis did not take into account cases of mild ulcerative colitis, a subgroup in which appendicectomised patients may be overrepresented.

Finally, we do not believe that the effect of appendicectomy on the course of ulcerative colitis is so high that it would remain after excluding all patients without appendicitis, thus probably two thirds of our patients. A key point however, like in the TCR-α knockout mouse model, is the date of appendicectomy. Appendicectomy protects against severe ulcerative colitis only when performed at a young age, and therefore disease onset. This latter observation argues against any therapeutic effect of appendicectomy after onset of ulcerative colitis. The problem is different when considering patients at risk for the disease.

We do believe that in a few years it will be possible to screen out young patients with a decreased risk of ulcerative colitis, suggesting that appendicitis rather than appendicectomy protects against ulcerative colitis. Cosnes et al state that these results may not be correct as they included all patients with previous appendicectomy and still found a less severe course. We believe they are incorrectly assuming this, as another possible explanation is that the effect of appendicitis is actually higher than the effect of appendicectomy reported in the present study, which could have been due to the inclusion of patients without appendicitis.

In conclusion, we believe that at present healthy persons at risk of developing ulcerative colitis should not be considered candidates for appendicectomy outside clinical trials as evidence showing that appendicectomy will protect these persons is lacking.
predisposing genotype for ulcerative colitis, and a clinical trial assessing the benefits of prophylactic appendicectomy will be warranted.

J Cosnes, F Caronnel, L Beaugerie, J-P Geurie
Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, Paris, France

Correspondence to: Professor J Cosnes, Service de Gastroenterologie et Nutrition, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75251 Paris cedex 12, France; jacques.cosnes@sat-ap-hop.paris.fr

References

Screening and surveillance for asymptomatic colorectal cancer in IBD

We would like to voice our concerns about some of the recommendations in the guidelines recently published by the British Society of Gastroenterology and Association of Coloproctology for screening and surveillance for asymptomatic colorectal cancer in patients with inflammatory bowel disease (Gut 2001;48:326–35).

(1) In the present medicolegal environment, failure to comply with guidelines which carry the imprimatur of respected national bodies will require vigorous defence should mishap occur. We do not believe the evidence is strong enough to justify the recommendation that every patient with extensive colitis of duration greater than 8–10 years should undergo regular colonoscopy. Firstly, it must be determined at each hospital whether it is possible and considered sufficiently cost effective to offer such a service without the constraint of local resources available. Secondly, if regular colonoscopy can be offered, then each patient should decide whether or not to accept regular colonoscopy after full discussion of its possible advantages and limitations.

(2) The success of colonoscopic surveillance programmes is disputed. Although some centres (including our own) have been protagonists for this approach, others have argued that it is not only labour intensive but also ineffective. Before imposing global national guidelines we should have firm evidence of a scheme’s efficacy or, failing this, we should have multicentre consensus. The guidelines, as published, are the sincerely held opinions of a single consultant team based on their own research and assessment of the literature, followed by approval of a committee, but no indication is given of widespread consultation.

(3) The recommendations for patients with extensive colitis of duration every third year during the second decade of disease, every second year during the third decade, and annual colonoscopies thereafter are complex. The evidence for an increasing risk of cancer in the second, third, and succeeding decades of disease duration is controversial, and is not borne out by the unstratified figures for patients with non-ulcerative colitis based on 26 reported studies in the meta-analysis reported by the authors of the guidelines, although an increase was observed in stratified data.2 The strategy suggested therefore is not based on firm data, and in particular published data after the third decade are few due to the small numbers involved.

(4) We have concerns about the benefits of routine colonoscopic examinations of taking two to four random biopsy specimens every 10 cm. This approach is time consuming for both the colonoscopist and the pathology department, and adds a considerable financial burden to the programme (which is not included in Eaden and Mayberry’s cost analysis). In theory, the risk of a false negative examination is reduced as more biopsies are taken but in practice the additional yield is very low indeed. During a recent study at St Mark’s Hospital, almost 3000 random surveillance biopsies from such patients yielded no dysplasia (unpublished data).

(5) Considering the disputed efficacy of current colonoscopic surveillance programmes for patients with extensive ulcerative colitis, it is inappropriate at present to extend this by default to patients with left sided colitis or (by implication) those with Crohn’s disease.

A Forbes, S Gabe, J E Lennard-Jones, K Wilkinson
St Mark’s Hospital and Academic Institute, Watford Road, Harrow HA1 3UJ, UK
Correspondence to: Dr A Forbes, alasatir.forbes@ic.ac.uk

Reference

Authors’ reply

We would like to thank Dr Forbes et al for their response to the guidelines published by the British Society of Gastroenterology (BSG) and the Association of Coloproctology of Great Britain and Ireland on screening and surveillance for asymptomatic colorectal cancer in patients with inflammatory bowel disease (Gut 2001;48:326–35). We raise a number of points which will be answered in turn.

(1) There are medicolegal implications of failing to comply with recommendations from a respected body but a guideline is precisely that—a guideline. They are not etched in stone and may need to be amended at future dates to continue to reflect best practice. The case of Wilsher v Essex Area Health Authority demonstrates that even the highest standards, however, the courts (Early v Newham Health Authority) will consider local guidelines. This will be of particular importance to units that are unable to deliver standards that have been identified nationally, provided the local practice has been formulated into a local guideline.

There is a wealth of data supporting the increased cancer risk in patients with ulcerative colitis and although evidence of the effectiveness of surveillance as practised in many centres is uncertain, such an approach is widespread. The purpose of guidelines is to identify good practice and to achieve a uniform approach throughout the country. The alternatives are to abandon surveillance or to offer haphazard and unstructured (and ineffectual) service. The absence of surveillance for both colitis and Crohn’s patients is estimated to be £9600 per annum.

We feel that the evidence for the cost but we realise funds may not be available initially which is one of the reasons for suggesting the guidelines are audited in five years. It is clearly stated in the guidelines that a discussion should take place between the doctor and patient informing them of their individual risk so that the patient can make an informed decision before embarking on a surveillance programme. Gone are the days of a paternalistic attitude, as patients should now accept some responsibility for their illness.3

(2) Forbes et al raise the point that before any guidelines are imposed there should be firm evidence of a scheme’s efficacy. There are no randomised studies comparing different surveillance protocols or for that matter even other guidelines.4 We have concerns about the benefits of surveillance versus no surveillance. As Forbes et al are well aware, it will never be possible to provide grade A recommendations on this issue and the best we can do is to assess surveillance programmes retrospectively. Data are accumulating that surveillance participants have reduced morbidity and mortality, as outlined in the guidelines, and one of the signatories to your letter has stated that surveillance improves survival.5 One notable review of surveillance programmes from the Leeds group did not show any benefit from surveillance but the group had very stringent criteria.6 They felt inclusion of dysplasia alone as a measure of success was of debatable value. Therefore, they limited their audit to those eventually found to have cancer. They also decided to exclude patients in whom cancer was found at an initial colonoscopy undertaken at least 12 years after the onset of symptoms. We feel that finding dysplasia is the very aim of surveillance and because it is found on the first colonoscopy in a surveillance programme it should not be deemed a failure of surveillance.

As far as possible was obtained before the guidelines were published. A national audit of the surveillance practices of gastroenterologists was conducted which revealed that although 94% of gastroenterologists performed surveillance, there was wide variation in practice. This alone suggests there would be little chance of a consensus opinion across the UK. Once the guidelines had been formulated, the Clinical Services and Standards Committee comprising approximately 40 individuals reviewed them. They then went through the usual guidelines process after being seen by the Clinical Services Committee and was subsequently determined by the IBD section of the BSG. After this they were posted on the BSG website for six weeks to attract comments from other members of the society. The guidelines then went back to the Clinical Services Committee after amendments were made on the basis of comments from the wide range of consultants. Finally, the guidelines went before the Executive Committee of the BSG for a further review and signing off. Thus the guidelines are very well accepted and published. They are not simply the opinions of two consultant gastroenterologists.
(3) We appreciate that increasing the colonscopy frequency with increasing dura-
tion of disease is more complicated than 1–2
years surveillance. However, we are sure that it is not too difficult to calculate and it actually
reduces the number of colonoscopies being performed initially, so this must be regarded as
an improvement on the present routine practice of some gastroenterologists.

The meta-analysis does show an increasing cancer risk in the second and third decades of
disease. It is only stratified data that can be
used in this way. Such data will give the most
accurate estimate as it is only these data that
were not broken down for each decade. Even
with the unstratified data were examined the cancer incidence still increased by decade of
disease! The unstratified cumulative prob-
abilities give a risk of 4.4% (95% CI 2.0–6.8%)
at 10 years, 8.6% (95% CI 4.0–13.3%) at 20
years, and 12.7% (95% CI 6.0–19.3%) at 30
years.

The 26 studies Forbes et al refer to also included
patients with extensive ulcerative colitis, it
has been shown to have the same cancer risk as
patients by the third decade are few but this is
the nature of the beast. The use of a
meta-analysis of cancer risk in ulcerative col-
titis overcomes the inadequacies of any reliance
on smaller studies from single specialist cen-
tres.

(4) We accept that the cost of biopsies was
not included in the cost analysis. There are
numerous articles debating the number of
biopsies which should be taken during a sur-
veillance colonoscopy. Yes it is time consum-
ing, but we all know that to stand any chance of
detecting dysplasia, the more biopsies taken the better. What is the point in surveil-
lance at all if it is not conducted to the best
standards in terms of biopsies? Forbes and col-
leagues studied the annual incidence of Crohn's
disease in Caucasian, African, Asian, and His-
panic individuals, with an observed range from
4.36 per 100 000 population for Cauca-
sian, 29.8 for African, 5.6 for Asian, and 4.1 for
Hispanics. Recently, a genetic basis for Crohn's
disease has been described. The CARD15
3% and 1% for G908R, and 3% and 0% for
1007fs (p<0.05 in all cases). None of the vari-
ants was observed in the Asian population,
consistent with a recent study of Japanese
patients with Crohn's disease.3 The ethnic
variation seen here could, in part, contribute
to the variations in the frequency of Crohn's
disease and the different clinical presentations.

The whole point of stratified data was to see if
such an approach, are that of
the nature of the beast. The use of a
meta-analysis of cancer risk in ulcerative col-
titis overcomes the inadequacies of any reliance
on smaller studies from single specialist cen-
tres.

(4) We accept that the cost of biopsies was
not included in the cost analysis. There are
numerous articles debating the number of
biopsies which should be taken during a sur-
veillance colonoscopy. Yes it is time consum-
ing, but we all know that to stand any chance of
detecting dysplasia, the more biopsies taken the better. What is the point in surveil-
lance at all if it is not conducted to the best
standards in terms of biopsies? Forbes and col-
leagues studied the annual incidence of Crohn's
disease in Caucasian, African, Asian, and His-
panic individuals, with an observed range from
4.36 per 100 000 population for Cauca-
sian, 29.8 for African, 5.6 for Asian, and 4.1 for
Hispanics. Recently, a genetic basis for Crohn's
disease has been described. The CARD15
3% and 1% for G908R, and 3% and 0% for
1007fs (p<0.05 in all cases). None of the vari-
ants was observed in the Asian population,
consistent with a recent study of Japanese
patients with Crohn's disease.3 The ethnic
variation seen here could, in part, contribute
to the variations in the frequency of Crohn's
disease and the different clinical presentations.

The whole point of stratified data was to see if
such an approach, are that of
the nature of the beast. The use of a
meta-analysis of cancer risk in ulcerative col-
titis overcomes the inadequacies of any reliance
on smaller studies from single specialist cen-
tres.

(4) We accept that the cost of biopsies was
not included in the cost analysis. There are
numerous articles debating the number of
biopsies which should be taken during a sur-
veillance colonoscopy. Yes it is time consum-
ing, but we all know that to stand any chance of
detecting dysplasia, the more biopsies taken the better. What is the point in surveil-
lance at all if it is not conducted to the best
standards in terms of biopsies? Forbes and col-
leagues studied the annual incidence of Crohn's
disease in Caucasian, African, Asian, and His-
panic individuals, with an observed range from
4.36 per 100 000 population for Cauca-
sian, 29.8 for African, 5.6 for Asian, and 4.1 for
Hispanics. Recently, a genetic basis for Crohn's
disease has been described. The CARD15
3% and 1% for G908R, and 3% and 0% for
1007fs (p<0.05 in all cases). None of the vari-
ants was observed in the Asian population,
consistent with a recent study of Japanese
patients with Crohn's disease.3 The ethnic
variation seen here could, in part, contribute
to the variations in the frequency of Crohn's
disease and the different clinical presentations.

The whole point of stratified data was to see if
such an approach, are that of
the nature of the beast. The use of a
meta-analysis of cancer risk in ulcerative col-
titis overcomes the inadequacies of any reliance
on smaller studies from single specialist cen-
tres.

(4) We accept that the cost of biopsies was
not included in the cost analysis. There are
numerous articles debating the number of
biopsies which should be taken during a sur-
veillance colonoscopy. Yes it is time consum-
ing, but we all know that to stand any chance of
detecting dysplasia, the more biopsies taken the better. What is the point in surveil-
lance at all if it is not conducted to the best
standards in terms of biopsies? Forbes and col-
leagues studied the annual incidence of Crohn's
disease in Caucasian, African, Asian, and His-
panic individuals, with an observed range from
4.36 per 100 000 population for Cauca-
sian, 29.8 for African, 5.6 for Asian, and 4.1 for
Hispanics. Recently, a genetic basis for Crohn's
disease has been described. The CARD15
3% and 1% for G908R, and 3% and 0% for
1007fs (p<0.05 in all cases). None of the vari-
ants was observed in the Asian population,
consistent with a recent study of Japanese
patients with Crohn's disease.3 The ethnic
variation seen here could, in part, contribute
to the variations in the frequency of Crohn's
disease and the different clinical presentations.

The whole point of stratified data was to see if
such an approach, are that of
the nature of the beast. The use of a
meta-analysis of cancer risk in ulcerative col-
titis overcomes the inadequacies of any reliance
on smaller studies from single specialist cen-
tres.

(4) We accept that the cost of biopsies was
not included in the cost analysis. There are
numerous articles debating the number of
biopsies which should be taken during a sur-
veillance colonoscopy. Yes it is time consum-
ing, but we all know that to stand any chance of
detecting dysplasia, the more biopsies taken the better. What is the point in surveil-
lance at all if it is not conducted to the best
standards in terms of biopsies? Forbes and col-
leagues studied the annual incidence of Crohn's
disease in Caucasian, African, Asian, and His-
panic individuals, with an observed range from
4.36 per 100 000 population for Cauca-
sian, 29.8 for African, 5.6 for Asian, and 4.1 for
Hispanics. Recently, a genetic basis for Crohn's
disease has been described. The CARD15
3% and 1% for G908R, and 3% and 0% for
1007fs (p<0.05 in all cases). None of the vari-
ants was observed in the Asian population,
consistent with a recent study of Japanese
patients with Crohn's disease.3 The ethnic
variation seen here could, in part, contribute
to the variations in the frequency of Crohn's
disease and the different clinical presentations.

The whole point of stratified data was to see if
such an approach, are that of
the nature of the beast. The use of a
meta-analysis of cancer risk in ulcerative col-
titis overcomes the inadequacies of any reliance
on smaller studies from single specialist cen-
tres.
An elderly man was admitted to hospital with severe anaemia. The houseman obtained a history of aspirin ingestion and, over the preceding few weeks, recurrent melena. He described feeling a hard liver edge. A blood count showed haemoglobin (Hb) 4.3, mean corpuscular volume (MCV) 55.7, white blood cell count (WCC) 6.6, and platelets 63. The patient was transfused and without further investigation the physician/gastroenterologist arranged for oesophago-gastro-duodenoscopy (OGD) and colonoscopy. At OGD the stomach was described as showing a moderate erythematous/exudative gastritis. At colonoscopy no abnormality was seen apart from a little fresh bleeding, the cause of which was not apparent. The patient was therefore only to be admitted for 36 hours later with faecal peritonitis. The colon had been perforated at the rectosigmoid junction. The patient recovered well from reparative surgery but died six weeks later of multorgan failure. At necropsy he was found to have cirrhosis of the liver. In retrospect, photographs of the gastric mucosa were consistent with portal gastropathy.

Case No 2

An elderly man taking diclofenac for osteoarthritis of the hip began drinking heavily after the death of his wife. One Saturday he felt faint, vomited black fluid, and passed melena. After the weekend he was admitted to hospital. His blood count showed Hb 9.7, MCV 105, WCC 10.3, and platelets 240. As in case No 1, he was listed for OGD and colonoscopy. At OGD he was found to have a marked antral gastritis and multiple duodenal erosions in a deformed duodenal cap. At colonoscopy, multiple diverticulae were found in the sigmoid one of which was instrumental perforation occurred. The patient was referred promptly for surgery. There was little faecal contamination and the patient recovered well after resection of a short length of colon.

In both of these cases the physician-gastroenterologists appeared to be working to the dictum: bleeding from the gut requires investigation the physician/gastroenterologist should cite trials of SASP versus newer agents to those wishing to use the least expensive treatment or clinical studies. Tissue level studies have indicated that double dose mesalazine is delivered to the kidney, not the colon. A large clinical trial of Pentasa in mild to moderate active UC found remission rates of 29% for both 2 g/day and 4 g/day. This latter study highlights the lack of efficacy of mesalazine released by a drug delivery system in active UC. In contrast, three studies comparing balsalazide with mesalazine (pH dependent release), containing a total of 926 patients found balsalazide to be superior in active UC, with rapid resolution of symptoms (median 10 days in one study) and superior sigmoidoscopic scores (in all three studies). Plasma concentrations of 5-aminosalicylic acid (5-ASA) were 4.5-fold lower in patients treated with balsalazide than mesalazine (p=0.018). Patients with most to benefit are new patients with distal disease. The use of 5-ASA in the initial treatment of UC does not require mega doses, as Dr Travis suggests, indeed mega doses of mesalazine delivered by Asacol or Pentasa are ineffectual, but it does require a reliable delivery system, such as the azo bond, and an inert carrier, as with balsalazide. The clinical implication of this efficacy in mild to moderate active UC is that the threshold for the use of steroids can be raised. Of interest in the North American trials of balsalazide versus mesalazine, 60 patients failing mesalazine therapy were treated after the trial with balsalazide open label, with 60% response (data on file, Shire Pharmaceuticals Ltd).

References

1 Kruis W, Schreiber S, Theuer D, et al. Low doses balsalazide [1.5 g twice daily] and mesalazine [0.5 g three times daily] maintained remission of ulcerative colitis but high dose balsalazide [3 g twice daily] was superior in preventing relapses. Gut 2001; 49:733–9.
8 Green JRB, Mansfield JC, Gibson JA, et al. A double blind comparison of balsalazide 67.5 g daily and sulfasalazine 5 g daily in patients with newly diagnosed or recently relapsed active ulcerative colitis. Aliment Pharmacol Ther 2003; 16:9–18.
TIPS for gastric varices

We recently read with interest the study by Tripathi and colleagues investigating the outcome of TIPS in patients with gastric (GV) compared to oesophageal varices (OV). This study confirmed the previous finding of lower mean portosystemic pressure gradient (PPG) in patients with GV bleeding relative to those with a history of OV bleeding. Indeed in this study 35% (14/40) of GV patients compared to only 8% (20/232) of OV patients had a PPG <12 mm Hg. The group of patients who bled at PPG <12 mm Hg (group 1) is particularly intriguing. As mentioned by the authors, low PPG in GV patients has been related to the presence and size of a spontaneous gastrorenal shunt (GRS) which is present in up to 15% of GV patients but present in only about 20% of OV patients. Previously, Sanjay et al. found that 50% (6/12) of patients who underwent TIPS for prevention of GV re-bleeding failed to decompress the varices as documented by endoscopy, 4/6 of these patients had a large GRS and a PPG <12 mm Hg. Thus based on probability, the group 1 patients in the current study (both GV and OV) are likely to have had a spontaneous GRS already decompressing the portal system. It would be valuable to know if the authors have any data on the presence of GRS in their patient population, perhaps documented by portogram taken at the time of TIPS. Also, did they document decompression of varices post-TIPS as an indicator of the clinical efficacy of the procedure? For example, it would be interesting to know if patients in group 1 failed to decompress varices post-TIPS more often than patients in group 2. Additionally, we have experience of a number of patients with large GV who had a baseline PPG <12 mm Hg and a large GRS. Following TIPS in these patients, there was a minimal or no reduction in PPG and filling of the GV was not shown to be reduced on post-TIPS portogram.

Finally the authors noted in group 2 (baseline PPG >12 mm Hg) that lower post-TIPS PPG was associated with a lower risk of bleeding which would be hoped. However in group 1, there was no difference in post-TIPS PPG between patients who did and did not re-bleed, suggesting that PPG may not be a critical determinant of variceal bleeding in patients who have a low PPG to start with. The role of PPG in dictating the natural history of GV is not known. Conceptually, insertion of an artificial portosystemic shunt into a patient who already has a large spontaneous shunt effectively offloading the portal pressure would not seem to confer much benefit. Do these GV (and possibly OV) patients with low PPG pre-TIPS and with a possible GRS really benefit from TIPS?

MR angiography can accurately assess for presence of a spontaneous GRS. There is a compelling argument that this should be an essential part of the assessment algorithm of patients with GV if a large spontaneous shunt is present, and PPG (as measured by hepatic vein wedge pressure gradient (HVPG)) is <12 mm Hg, then perhaps other therapeutic options such as B-RT0 (balloon occluded retrograde transvenous obliteration) should be considered. Hopefully more prospective data, examining the role of PPG, TIPS, and B-RT0 in the management and outcome of GV will help clarify these issues.

B M Ryan, R W Stockbarger
University Hospital Maastricht, Maastricht, The Netherlands

J M Ryan
Division of Interventional Radiology, Duke University Medical Centre, Durham, North Carolina

Correspondence to Dr Ryan, Department of Gastroenterology, University Hospital Maastricht, Postbus 5800, 6202 AZ Maastricht, The Netherlands; bryan@planet.nl

References


Authors’ reply

We agree that the presence of gastrorenal shunts (GRS) is likely to explain the low portal pressure gradient (PPG) post-transjugular intrahepatic portosystemic stent shunt (TIPS). Portography at the time of index TIPS insertion was primarily performed to identify varices and not specifically to look for the presence of GRS, although the splenic vein was visualised if not always in its entirety. Given these limitations, we have looked at the portograms of over 400 patients who have had TIPS for any cause, and identified shunts in 38%. For the study period, we used a post-TIPS PPG <12 mm Hg as an indicator of the efficacy of the TIPS procedure for patients with both gastric and oesophageal varical bleeding. In light of our findings we have revised our target PPG post-TIPS to <7 mm Hg.

Our finding of a lack of a statistical difference in the post-TIPS PPG of those patients who did or did not rebleed may be due to the small numbers in group 1. It may be that factors other than portal pressure such as variceal size and variceal wall tension play an important part in the risk of variceal bleeding in patients with a PPG of <12 mm Hg. It is also true that portal pressure directly affects the variceal wall tension, and attempts to reduce the portal pressure by a TIPS will be beneficial. We strongly believe that TIPS has a significant role in patients who have refractory gastric varical bleeding, as mirrored by studies from others.1 At the present time it is the most effective non-surgical method of treating gastric varical haemorrhage and preventing rebleeding. Other therapeutic options are promising, and we have previously reported on the effective use of human thrombin in the treatment of acute gastric varical haemorrhage.1 However, controlled studies are required before universal recommendation of endoscopic therapies for gastric varical haemorrhage.

D Tripathi, G Therapondos, P C Hayes
Centre for Liver and Digestive Disorders and Department of Medicine, the Royal Infirmary, Edinburgh, UK

D N Redhead
Department of Radiology, the Royal Infirmary, Edinburgh, UK

Correspondence to: D Tripathi, Department of Medicine, Royal Infirmary of Edinburgh, Edinburgh Place, Edinburgh EH3 9YW, UK; d.tripathi@ed.ac.uk

References


ABc of Liver, Pancreas and Gall Bladder


The ABC Series are well established as handy reference guides but they sometimes struggle from not being clear about their target readership. midway between a textbook and an update, this publication follows the usual format. The topic is covered from investigations used in liver and biliary disease to the clinical conditions themselves, ranging from gall stones to liver and pancreatic transplantation. Because of the nature of the clinical area, the book will probably appeal more to the hospital clinician than the general practitioner although the latter will gain much in having a source of reference for unusual and awkward clinical situations. Although the list of topics is complete, there are still problems in interpreting some of the information for use in the pragmatic clinical setting. The section on gall stones, for example, while full of detail of anatomy and presentation does not make it any easier for the clinician trying to decide whether to refer the patient with stones or when cholecystectomy is indicated. It may well be that in some areas, such as gall stone management, clinical judgement still outdstances evidence but it would have been useful to have had

www.gutjnl.com

Gut: first published as 10.1136/gut.52.5.770-a on 1 May 2003. Downloaded from http://gut.bmj.com/ on April 21, 2022 by guest. Protected by copyright.
at the stage of abnormal bleeding. This is a true master at work!...
Prague Hepatology Meeting
To be held on 5–7 June 2003 in Prague, Czech Republic. Leading speakers from Europe and the USA will present new ideas and suggestions on pathophysiology, diagnostics, and therapy of liver diseases in ten programmes blocks. Further details: Ms Veronica Revicka. Tel: +420 241 445 759; fax: +420 241 445 806; email: veronika@congressprague.cz

Falk Symposia—New Findings on Pathogenesis and Progress in Management of IBD
Two symposia and a workshop will be held on 10–14 June 2003 in Berlin, Germany. Further details: Falk Foundation e.V., Congress Division, PO Box 6529, Leinenweberstr. 5, 79041 Freiburg/Bt, Germany. Tel: +49 761 15 140; fax: +49 761 15 14 399; email: symposia@falkfoundation.de; website: www.falkfoundation.de

Gastroenterology and Endotherapy: XXIst European Workshop
This will be held on 16–18 June 2003 in Brussels, Belgium. Further details: Nancy Beauprez, Administrative Secretariat of the Workshop, Gastroenterology Department, Erasme Hospital, Route de Lennik 808, B-1070 Brussels, Belgium. Tel: +32 (0)2 555 49 00; fax: +32 (0)2 555 49 01; email: beauprez@ulb.ac.be

European Helicobacter Study Group (EHSG)
This meeting, on Helicobacter infections and gastroduodenal pathology, will be held on 3–6 September 2003 in Stockholm, Sweden. Further details: Professor Torkel Wadstrom, President- EHSG, Lund University, Department of Infectious Diseases & Medical Microbiology, Division of Bacteriology, Solvegatan 23, SE-223 62 Lund, Sweden. Tel: +46 46 173 241; fax: +46 46 152 564; email: Torkel.Wadstrom@mmb.lu.se; website: www.helicobacter.org

Falk Symposium 135—Immunological Diseases of Liver and Gut
This symposium will be held on 12–13 September 2003 in Prague, Czech Republic. Further details - see Falk Symposia above

The Association of Coloproctology of Great Britain & Ireland
This annual meeting will be held on 7–10 July 2003 in Edinburgh, UK. Further details: Conference Secretariat, The ACGBI at the Royal College of Surgeons of England, 35–43 Lincoln’s Inn Fields, London WC2A 3PE. Tel: +44 (0)20 7973 0307; fax: +44 (0)20 7430 9235; email: acpgb@asgbi.org.uk; website: www.acpgbi.org.uk

The European Society of Parenteral and Enteral Nutrition (ESPEN)
ESPEN will celebrate its silver anniversary at the time of the annual congress, which is to be held on 20–23 September 2003 in Cannes, France. Further details: www.espen.org

XII Falk Liver Week
The XII Falk Liver Week, in honour of Hans Popper’s 100th birthday, will be held on 15–22 October 2003 in Freiburg, Germany. Further details - see Falk Symposia above.

European Course on Laparoscopic Endoscopy
This course will be held on 18–21 November 2003 in Brussels, Belgium. Further details: Secretary to Professor Cadière, Service de Chirurgie Digestive, Rue Haute 322, Brussels 1000, Belgium. Tel: +32 (0)2 648 07 60; fax: +32 (0)2 647 86 94; email: straeb.asmb@proximedia.be; website: www.straeb-asmb.com

Hong Kong-Shanghai International Liver Congress 2004
This conference will be held on 14–17 February 2004 in Hong Kong. The topic of the conference is “Liver Diseases in the Post-Genomic Era”. Further details: Ms Kristie Leung, Room 102–105 School of General Nursing, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong. Tel: +852 2818 4300/8101 2442; fax: +852 2818 4030; email: kristieleung@hepa2004.org; website: www.hepa2004.org

What's in the next issue

Future content

See which articles have just been accepted for publication and preview the table of contents for the next issue a month before it is published

www.gutjnl.com

www.gutjnl.com